Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
  • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
  • C07D221/04—Ortho- or peri-condensed ring systems
  • C07D221/06—Ring systems of three rings
  • C07D221/10—Aza-phenanthrenes
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system

Definitions

• the present invention is related to new substituted octahydrobenzo(f)quinolines as defined below, to processes for preparing such compounds as well as to pharmaceutical preparations thereof and methods of treatment employing such compounds.
• An object of the invention is to provide specific compounds for therapeutic use, especially having a therapeutic activity in the central nervous system.
• Cannon et al. J. Med. Chem. 23,1 (1980) also describe compounds wherein Y' is 8-OH (or 8-OCH 3 ), Y" is 9-OH (or 9-OCH 3 ) and R' is H, CH 3 , C 2 H 5 or n-C 3 H 7 . Said compounds are claimed to be inactive in the central nervous system but to be potent dopamine agonists in the periphery.
• Wikstrom et al. (J. Med. Chem., 1982, 25, 925 ⁇ 931) describe compounds under the above formula wherein Y" is H, Y' is 7-OH, 8-OH, 9-OH and 10-OH and R' is n-Pr and n-Bu having dopaminergic properties. However, these compounds stimulate both presynaptic and postsynaptic dopamine receptors.
• the hydroxy compounds mentioned were prepared by demethylating the corresponding methoxy compounds. In the preparation of those methoxy compounds, intermediates are employed wherein Y" is H, Y' is CH 3 0 and R' is H.
• DE-A-20 44 172 describes compounds under the formula wherein R' and R" represent H or alkyl, X' represents H 2 or 0 and Y' represents H, alkoxy or hydroxy. Said compounds are claimed to have analgesic activity.
• EP-A-54553 describes 10-methoxy-7-subst.-octahydrobenzo(f) quinolines with a centrally acting alpha, agonist activity. These compounds act on the adrenergic system in CNS.
• An alkyl group may be a straight alkyl group or a branched alkyl group having at least 3 carbon atoms.
• Both organic and inorganic acids can be employed to form non-toxic pharmaceutically acceptable acid addition salts of the compounds of this invention.
• Illustrative acids are sulfuric, nitric, phosphoric, hydrochloric, citric, acetic, lactic, tartaric, pamoic, ethanedisulfonic, sulfamic, succinic, cyclohexylsulfamic, fumaric, maleic and benzoic acid.
• These salts are readily prepared by methods known in the art.
• the invention is related to compounds of the formula I above wherein Y is OH, R'COO, or R 2 R 3 NCOO ⁇ , whereby R' is an alkyl group having 1-5 carbon atoms, or a phenyl group, and R 2 is an alkyl group having 1-5 carbon atoms, a phenethyl, benzyl or phenyl group, and R 3 is H or an alkyl group having 1-5 carbon atoms.
• One group of preferred compounds are those wherein Y is OH or R 2 R 3 NCOO. Further preferred are compounds wherein R is H or 4-hydroxybutyryl.
• Preferred compounds are those wherein Y is OH and R is H or 4-hydroxybutyryl.
• the compounds of formula I contain two asymmetric carbon atoms in the aliphatic moiety as indicated by asterisks in the above formula.
• the therapeutic properties of the compounds are ascribed to the trans isomers.
• the pure enantiomers as well as mixtures thereof are within the scope of the invention.
• the preferred enantiomers are those with 4aS,10bS-configuration.
• the compounds of the invention may be obtained by one of the following methods constituting a further aspect of the invention.
• R a represents a hydrocarbon residue, preferably an alkyl group having 1-5 carbon atoms, or a benzyl group, and R is as defined above, may be cleaved to form a compound of formula I wherein Y is a hydroxy group.
• the cleavage may be carried out by treating the compound of formula II with an acidic nucleophilic reagent such as aqueous HBr, or HI, HBr/CH 3 COOH, BBr 3 , AICI 3 , pyridine-HCI or (CH 3 ) 3 Sil, or with a basic nucleophilic reagent such as CH 3 C 6 H 4 ⁇ S ⁇ or C 2 H 5 -S ⁇ .
• an acidic nucleophilic reagent such as aqueous HBr, or HI, HBr/CH 3 COOH, BBr 3 , AICI 3 , pyridine-HCI or (CH 3 ) 3 Sil
• a basic nucleophilic reagent such as CH 3 C 6 H 4 ⁇ S ⁇ or C 2 H 5 -S ⁇ .
• R a is a benzyl group
• the cleavage may also be carried out by reduction, preferably with hydrogen using Pd or Pt0 2 as catalyst.
• a compound of formula II wherein R a is a methyl group is obtained from a compound of formula IIA, as described in J. Med. Chem. 1982, 25, 925.
• Compounds of formula II wherein R a is an alkyl group with 2-5 carbon atoms are synthesized in an analogous manner starting from the appropriately substituted compound IIA.
• a compound of formula wherein Y is OH and R is as defined above may be converted into a compound of the formula I wherein Y is R'COO, R 2 R 3 NCOO or R 4 0 by treating the first mentioned compound with an appropriate carboxylic acid halide R'COX or anhydride (R'CO)20 or with an appropriate carbamoyl halide R 2 R 3 NCOX in the presence of a base (only when R is other than hydrogen) such as triethylamine or pyridine or an acid such as H 2 SO 4 or CF 3 COOH or with an appropriate allyl, benzyl or methyl halide R 4 X in the presence of a base such as triethylamine, pyridine or potassium t-butoxide.
• X represents a halogen, preferably CI or Br.
• R' is a compound of formula I wherein Y is OH
• R' is a compound of formula I wherein Y is OH
• a compound of the formula wherein Y is other than allyloxy may be hydrogenated to form a compound of formula I wherein R is H.
• the hydrogenation is carried out in the presence of a catalyst such as Pd.
• the starting material of formula IV is obtained by demethylation of the corresponding methoxy compound described in J. Med. Chem. 1982,25, 925 ⁇ 931, and, when Y other than OH is required, subsequent acylation in analogy with b) above.
• An amide of the formula wherein Y is other than R 2 R 3 NCOO may be converted into a compound of the formula I by reduction of the amide function and the ester function R'COO if present.
• the compound of formula V may be treated with a reducing agent preferably a hydride reducing agent such as LiAIH 4 or BH 3 in an ethereal solvent or a metal reducing agent such as Na in an alcoholic solvent such as n-butanol.
• a reducing agent preferably a hydride reducing agent such as LiAIH 4 or BH 3 in an ethereal solvent or a metal reducing agent such as Na in an alcoholic solvent such as n-butanol.
• a compound according to the formula wherein one of the groups Z 1 and Z 2 is a leaving group X and the other is NH 2 , or Z 1 and Z 2 are both leaving groups X, and X is a leaving group such as Cl, Br, I or ⁇ OSO 2 C 6 H 4 CH 3 , may be converted to a compound of formula I wherein Y is as defined above and R is H, by treating the compound of formula VI, or when one of Z 1 and Z 2 is NH 2 , an acid addition salt thereof, with a base such as (C 2 H 5 ) 3 N or K 2 CO 3 , whereby the compound of formula VI is treated together with an equivalent amount of ammonia or an acid addition salt thereof when Z 1 and Z 2 are both X.
• the conversion is carried out in a solvent such as tetrahydrofuran, dioxan or acetonitrile, if necessary with simultaneous or subsequent heating of the mixture.
• a carbonyl-containing compound of the formula wherein Y is other than allyloxy may be subjected to an intramolecular reductive alkylation, preferably by using catalytic hydrogenation, to give a compound of the formula I wherein R is hydrogen.
• R is hydrogen
• a hydroxy group may be substituted for the group Z to the formation of a compound of formula I wherein Y represents a hydroxy group.
• said reaction may be carried out by treatment with a strong alkali under heating, suitably with an alkali melt such as KOH when Z is S0 3 H, and with a strong aqueous alkali such as NaOH or KOH when Z is Cl.
• Z is NH 2 the reaction may be carried out by treatment with aqueous nitrous acid to the formation of an intermediate diazonium compound which is then subjected to hydrolysis in water.
• a racemic mixture or a mixture partly enriched on one of the enantiomers of a compound of formula may be subjected to enantiomeric separation to obtain the desired enantiomer of compound I. This may be done by methods known in the art. These methods include recrystallization of diastereomeric salts with pure enantiomers of acids such as tartaric acid, O,O'-dibenzoyltartaric acid, mandelic acid and camphor-10-sulphonic acid.
• Free bases formed may subsequently be converted into their acid addition salts, and acid addition salts formed may subsequently be converted into the corresponding bases or other acid addition salts.
• the compounds of the present invention will normally be administered orally, rectally, or by injection, in the form of pharmaceutical preparations comprising the active ingredient either as a free base or as a pharmaceutically acceptable non-toxic, acid addition salt, e.g. the hydrochloride, lactate, acetate, sulfamate, and the like, in association with a pharmaceutically acceptable carrier.
• a pharmaceutically acceptable non-toxic, acid addition salt e.g. the hydrochloride, lactate, acetate, sulfamate, and the like, in association with a pharmaceutically acceptable carrier.
• the carrier may be a solid, semisolid or liquid diluent or capsule.
• These pharmaceutical preparations constitute a further aspect of this invention.
• the active substance will constitute between 0.1 and 99% by weight of the preparation, more specifically between 0.5 and 20% by weight for preparations intended for injection and between 0.2 and 95% by weight for preparations suitable for oral administration.
• compositions containing a compound of this invention in a solid form of dosage units for oral application may preferably contain between 2 and 95% by weight of the active substance, in such preparations the selected compound may be mixed with a solid fine grain carrier, e.g. lactose, saccharose, sorbitol, mannitol, starches such as potato starch, corn starch or amylopectin, cellulose derivatives, or gelatin and a lubricant such as magnesium stearate, calcium stearate, polyethylene glycol waxes, and the like, and then compressed to form tablets. If coated tablets are required, the cores, prepared as described above, may be coated with a concentrated sugar solution which may contain, e.g.
• the tablet can be coated with a lacquer dissolved in a readily volatile organic solvent or mixture of organic solvents.
• Dyestuffs may be added to these coatings in order to readily distinguish between tablets containing different active substances or different amounts of the active compound.
• soft gelatin capsules pearl-shaped closed capsules consisting of gelatin and, for example, glycerol, or similar closed capsules
• the active substance may be admixed with a vegetable oil.
• Hard gelatin capsules may contain granulates of the active substance in combination with solid, fine grain carriers such as lactose, saccharose, sorbitol, mannitol, starches (e.g. potato starch, corn starch or amylopectin), cellulose derivatives or gelatin.
• Liquid preparations for oral application may be in the form of syrups or suspensions, for example, solutions containing from about 0.2% to about 20% by weight of the active substance herein described, the balance being sugar and a mixture of ethanol, water, glycerol and propylene glycol.
• Such liquid preparations may contain colouring agents, flavouring agents, saccharine and carboxymethylcellulose as a thickening agent.
• Solutions for parenteral applications by injection can be prepared in an aqueous solution of a watersoluble pharmaceutically acceptable salt of the active substance preferably in a concentration of from about 0.5% to about 10% by weight.
• These solutions may also contain stabilizing agents and/or buffering agents and may conveniently be provided in various dosage unit ampoules.
• the suitable daily doses of the compounds of the invention are 50-10000 mg for oral application, preferentially 200-5000 mg, and 0.005-500 mg for parenteral application, preferentially 0.25-250 mg.
• 500 g of active substance are mixed with 500 g of corn oil, whereupon the mixture is filled in soft gelatine capsules, each capsule containing 100 mg of the mixture (i.e. 50 mg of active substance).
• 0.5 kg of active substance are mixed with 0.2 kg of silicic acid of the trade mark Aerosil. 0.45 kg of potato starch and 0.5 kg of lactose are mixed therewith and the mixture is moistened with a starch paste prepared from 50 g of potato starch and distilled water, whereupon the mixture is granulated through a sieve. The granulate is dried and sieved, whereupon 20 g of magnesium stearate are mixed into it. Finally the mixture is pressed into tablets each weighing 172 mg.
• Active substance (hydrobromide) (1 g), sodium chloride (0.8 g) and ascorbic acid (0.1 g) are dissolved in sufficient amount of distilled water to give 100 ml of solution.
• This solution which contains 10 mg of active substance per ml, is used in filling ampoules, which are sterilized by heating at 120°C for 20 minutes.
• the compounds of the invention under consideration are centrally acting selective dopamine auto- receptor stimulating agents, and thus of great clinical interest in the treatment of psychotic disorders such as schizofrenia and a number of other disease states such as tardive dyskinesia, Huntington's chorea, alcoholism and drug abuse, said psychotic disorders and other disease states possibly being associated with a pathological increase in central dopamine transmission.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Pharmacology & Pharmacy (AREA)
• Neurosurgery (AREA)
• Biomedical Technology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Neurology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Priority Applications (1)

Applications Claiming Priority (2)

Publications (2)

Family

ID=20350972

Family Applications (2)

Family Applications Before (1)

Country Status (22)

Families Citing this family (21)

Citations (1)

Family Cites Families (5)

• 1983
  • 1983-04-27 SE SE8302361A patent/SE8302361D0/xx unknown
• 1984
  • 1984-04-04 ZA ZA842539A patent/ZA842539B/xx unknown
  • 1984-04-12 DE DE8484901820T patent/DE3479724D1/de not_active Expired
  • 1984-04-12 AU AU28667/84A patent/AU572840B2/en not_active Ceased
  • 1984-04-12 WO PCT/SE1984/000135 patent/WO1984004303A1/en active IP Right Grant
  • 1984-04-12 EP EP84850121A patent/EP0127597B1/en not_active Expired
  • 1984-04-12 HU HU842280A patent/HU193576B/hu not_active IP Right Cessation
  • 1984-04-12 EP EP84901820A patent/EP0172821B1/en not_active Expired
  • 1984-04-12 JP JP59501791A patent/JPS60501157A/ja active Granted
  • 1984-04-12 IE IE908/84A patent/IE57883B1/en not_active IP Right Cessation
  • 1984-04-17 NZ NZ207881A patent/NZ207881A/en unknown
  • 1984-04-19 US US06/601,981 patent/US4612316A/en not_active Expired - Fee Related
  • 1984-04-23 PH PH30593A patent/PH24764A/en unknown
  • 1984-04-26 DD DD84262369A patent/DD216716A5/de not_active IP Right Cessation
  • 1984-04-26 GB GB08410624A patent/GB2138815B/en not_active Expired
  • 1984-04-26 IS IS2906A patent/IS1365B6/is unknown
  • 1984-04-26 ES ES531931A patent/ES531931A0/es active Granted
  • 1984-04-26 CA CA000452852A patent/CA1264749A/en not_active Expired - Lifetime
  • 1984-04-27 KR KR1019840002260A patent/KR910007239B1/ko not_active IP Right Cessation
  • 1984-04-27 PT PT78512A patent/PT78512B/pt not_active IP Right Cessation
  • 1984-04-27 GR GR74542A patent/GR81994B/el unknown
  • 1984-12-21 DK DK620784A patent/DK159848C/da not_active IP Right Cessation
• 1985
  • 1985-01-31 ES ES540003A patent/ES8609258A1/es not_active Expired
  • 1985-05-24 FI FI852091A patent/FI82930C/fi not_active IP Right Cessation
• 1986
  • 1986-03-13 ES ES552962A patent/ES8801634A1/es not_active Expired
• 1987
  • 1987-08-01 ES ES557649A patent/ES8802032A1/es not_active Expired
• 1988
  • 1988-01-26 ES ES557808A patent/ES8900136A1/es not_active Expired

Patent Citations (1)

Also Published As

Similar Documents

Legal Events